Salta al contenuto principale
Passa alla visualizzazione normale.

MARIA MELI

Curriculum e ricerca

Insegnamenti

Anno accademico Codice della materia Nome della materia CFU Corso di studi
2020/2021 03143 FARMACOLOGIA -C.I. 8 MEDICINA E CHIRURGIA
2020/2021 99009 FARMACOLOGIA II (MODULO) 4 MEDICINA E CHIRURGIA

Pubblicazioni

Data Titolo Tipologia Scheda
2020 FARMACI INIBITORI DELLE TOPOISOMERASI Capitolo o Saggio Vai
2020 Meccanismi di resistenza ai farmaci antitumorali. Capitolo o Saggio Vai
2020 Farmaci antimicrotubulari Capitolo o Saggio Vai
2019 STAT5 and STAT5 Inhibitors in Hematological Malignancies Articolo in rivista Vai
2019 Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome Articolo in rivista Vai
2017 Farmaci antimicrotubulari Capitolo o Saggio Vai
2017 Effects of Pimozide Derivatives on pSTAT5 in K562 Cells Articolo in rivista Vai
2017 Farmaci inibitori delle topoisomerasi Capitolo o Saggio Vai
2017 Meccanismi di resistenza ai farmaci antitumorali Capitolo o Saggio Vai
2016 Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation Articolo in rivista Vai
2015 The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients Articolo in rivista Vai
2014 From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: Synthesis and biological evaluation of valproic esters of 3’-C-methyladenosine Articolo in rivista Vai
2014 Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives Articolo in rivista Vai
2014 4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors Articolo in rivista Vai
2013 Farmacovigilanza attiva sul ruolo dei farmaci antiangiogenetici nell’osteonecrosi dei mascellari Proceedings (TIPOLOGIA NON ATTIVA) Vai
2013 The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells. Articolo in rivista Vai
2013 The use of low molecular weight heparin in a Sicilian teaching hospital Proceedings (TIPOLOGIA NON ATTIVA) Vai
2012 Uso degli inibitori di pompa protonica in un Policlinico Universitario Articolo in rivista Vai
2012 Epigenetic agents as an adjunct to active chemotherapy in hematological tumor cell lines Proceedings (TIPOLOGIA NON ATTIVA) Vai
2011 Antitumor effects of novel co-drugs linking histone deacetylase and ribonucleotide reductase inhibitors in hematological tumors Proceedings (TIPOLOGIA NON ATTIVA) Vai
2011 Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3’-C-methyladenosine in leukaemia cells Articolo in rivista Vai
2009 Histone deacetylase (HDAC) inhibition modulates intracellular deoxynucleotides (dNTP) pools and potentiates the antitumor effects of the ribonucleotide reductase (RR) inhibitor 3’-Methyl-adenosine (3’-Me-Ado) in promyelocitic leukaemia cell lines. Proceedings (TIPOLOGIA NON ATTIVA) Vai
2008 Hydroxamic acid-containing histone deacetylase inhibitors potentiate the antiproliferative and apoptotic effects induced by the ribonucleotide reductase R1 inhibitor 3'-C-methyl-adenosine in promyelocytic leukemia cell lines Proceedings (TIPOLOGIA NON ATTIVA) Vai
2008 Histone deacetylase (HDAC) inhibitors potentiate the antiproliferative and apoptotic effects induced by the novel ribonucleotide reductase (RR) inhibitor 3'-metil-adenosine (3'-Me-Ado) in promyelocitic leukemia cell lines Proceedings (TIPOLOGIA NON ATTIVA) Vai
2008 Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives Articolo in rivista Vai
2008 Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells Articolo in rivista Vai
2007 The synergistic apoptotic effects of thiophenfurin, an inosine monophosphate dehydrogenase inhibitor, in combination with retinoids in HL60 cells. Articolo in rivista Vai
2007 Antitumor profile of new phenothiazine derivatives. Proceedings (TIPOLOGIA NON ATTIVA) Vai
2005 Cytotoxic and apoptotic effects of thiophenfurin in combination with retinoids in human promyelocitic leucemia HL60 cells Proceedings (TIPOLOGIA NON ATTIVA) Vai
2005 Farmaci antimicrotubulari. Monografia Vai
2005 Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells Articolo in rivista Vai
2005 Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possibile relationship to the effects on inhibitor of apoptosis protein levels Articolo in rivista Vai
2005 New trends in overcoming drug resistance in hepatocellular carcinoma. Looking for pharmacological inhibition of Inhibitory of Apoptosis Proteins (IAPs) by curcumin. Capitolo o Saggio Vai
2005 Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines Articolo in rivista Vai
2005 “Effects of combretastatin analogues on leukemic cell lines and normal hemopoietic cells” Proceedings (TIPOLOGIA NON ATTIVA) Vai
2004 Expression of the IAPs in multidrug resistant tumor cells Articolo in rivista Vai
2004 Expression of IAPs (Inhibitory of Apoptosis Proteins) and of their alternative splice variants in hepatocellular carcinoma tissues and cells Articolo in rivista Vai
2004 Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis Articolo in rivista Vai
2003 NF-kB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines Articolo in rivista Vai